Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 25 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

32%

8 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Phase 1
10(40.0%)
Phase 3
8(32.0%)
Phase 2
7(28.0%)
25Total
Phase 1(10)
Phase 3(8)
Phase 2(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT07452198Phase 3Recruiting

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT07348055Phase 1Recruiting

A Study of GR1803 in Systemic Lupus Erythematosus

Role: lead

NCT06516302Phase 3Active Not Recruiting

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Role: lead

NCT07199257Phase 3Not Yet Recruiting

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

Role: lead

NCT07199270Phase 1Recruiting

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

Role: lead

NCT07190716Phase 1Not Yet Recruiting

A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

Role: lead

NCT07154342Phase 3Recruiting

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

Role: lead

NCT07102706Phase 1Completed

Phase I Trial of GR1803 Injection in Patients With RRMM

Role: lead

NCT07090954Phase 1Not Yet Recruiting

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Role: lead

NCT06952075Phase 2Recruiting

GR1803 Injection in Patients With RRMM

Role: lead

NCT06566547Phase 2Recruiting

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT06315426Phase 2Active Not Recruiting

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Role: lead

NCT06642961Phase 2Unknown

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

Role: lead

NCT06635798Phase 3Recruiting

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Role: lead

NCT05873803Phase 2Active Not Recruiting

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

Role: lead

NCT05881785Phase 3Completed

Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis

Role: lead

NCT06015230Phase 1Active Not Recruiting

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Role: lead

NCT05846568Phase 3Completed

Study to Evaluate GR1801's Efficacy and Safety

Role: lead

NCT05954611Phase 1Completed

The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers

Role: lead

NCT06313697Phase 1Recruiting

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult

Role: lead